Exelixis | EXEL - Cost Of Sales

Stock Price
43.93
Daily Change
1.56 3.68%
Monthly
-4.89%
Yearly
31.21%
Q1 Forecast
40.09

Exelixis reported $18.57M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 21.65M 913K Sep/2025
Agios Pharmaceuticals USD 1.68M 22K Sep/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 2.8B 328M Sep/2025
Bayer EUR 4.31B 57M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Cytokinetics USD 112.55M 12.71M Jun/2025
Eisai JPY 45.52B 2.92B Sep/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Exelixis USD 18.57M 896K Sep/2025
Genmab DKK 57M 15M Jun/2025
Glaxosmithkline GBP 3.01B 853.01M Sep/2025
Incyte USD 99M 20.23M Sep/2025
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
MacroGenics USD 44.3M 5.4M Sep/2025
Merck USD 3.32B 531M Dec/2025
Moderna USD 207M 88M Sep/2025
Neurocrine Biosciences USD 264M 252.7M Sep/2025
Novartis USD 3.54B 217M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
Sanofi EUR 3.76B 344M Dec/2025
Takeda JPY 401.15B 184.07B Dec/2025
Ultragenyx Pharmaceutical USD 27.99M 4.99M Sep/2025
Xencor USD 61.66M 50.95M Jun/2025